Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss

Next Previous
Trial Profile

Efficacy and safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimapitide (Primary) ; Prednisolone
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HEALOS
  • Sponsors Altamira Therapeutics; Auris Medical

    • Most Recent Events

    • 11 Mar 2019 According to an Auris Medical media release, results detailing outcomes of this trial have been published in the journal Otology & Neurotology.
    • 07 May 2018 According to an Auris Medical media release, based on the result from this study, the company has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The company is also planning for a Type C meeting with the US FDA.
    • 04 Jan 2018 Pooled results from this and a phase II trial, published in an Auris Medical media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top